8-K/A

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

DC 20549

---

---

FORM

8-K/A

(Amendment No. 1)

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 28, 2022

LUCID DIAGNOSTICS INC.
(Exact<br> Name of Registrant as Specified in Charter)
Delaware	001-40901	82-5488042
---	---	---
(State<br> or Other Jurisdiction<br><br> <br>of<br> Incorporation)	(Commission<br><br> <br>File<br> Number)	(IRS<br> Employer<br><br> <br>Identification<br> No.)
One Grand Central Place, Suite 4600, New York, New York	10165
---	---
(Address<br> of Principal Executive Offices)	(Zip<br> Code)

Registrant’s telephone number, including area code: (212) 949-4319

N/A
(Former<br> Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading<br><br> <br>Symbol(s)	Name of each exchange on which registered
Common<br> Stock, Par Value $0.001 Per Share	LUCD	The<br> Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory

Note

---

On March 28, 2022, Lucid Diagnostics Inc. (the “Company”) furnished a Current Report on Form 8-K (“Original Form 8-K”) with the U.S. Securities and Exchange Commission to report that, on March 28, 2022, the Company issued a press release announcing financial results for its fiscal year ended December 31, 2021 and providing a business update (the “Original Earnings Release”). This Amendment No. 1 to the Original Form 8-K is being furnished to disclose a joint press release (the “Earnings Update Release”) of the Company and its majority owner, PAVmed Inc. (“PAVmed”), which includes an adjustment to Footnote #3 in the Original Earnings Release relating to the Company’s Non-GAAP measures for the allocation of Total Operating expenses for the fourth quarter.

---

Item 2.02.	Results of Operations and Financial Condition.

---

On March 28, 2022, the Company issued the Original Earnings Release. On March 29, 2022, the Company and PAVmed issued the Earnings Update Release, which includes an adjustment to one line item in the Original Earnings Release as described above. A copy of the Earnings Update Release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 7.01.	Regulation FD Disclosure.

---

The disclosure set forth under Item 2.02 is incorporated herein by reference.

The information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Company, except as shall be expressly set forth by specific reference in such document.

Item 9.01.	Financial Statements and Exhibits.

---

(d)	Exhibits:
Exhibit<br> No.	Description
---	---
99.1	Press release.
104.1	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 29, 2022

PAVMED INC.
By:	/s/ Dennis M. McGrath
	Dennis<br> M. McGrath
	Chief<br> Financial Officer

Exhibit99.1

---

PAVmedProvides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

Conferencecall to be held today at 4:30 PM EDT

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented preliminary financial results for the year ended December 2021.

ConferenceCall and Webcast

A conference call and webcast for today’s business update and fourth quarter and year ended December 31, 2021, financial results will take place at 4:30 PM EDT. To access the conference call, listeners should dial 877-407-3982 toll-free in the U.S. or 201-493-6780, and ask to join the “PAVmed, Inc. Business Update Conference Call”. The conference call will be available live via webcast and for replay at the investor relations section of the Company’s website at www.pavmed.com. Following the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing 844-512-2921 toll-free in the U.S. or 412-317-6671, followed by the PIN number: 13727143.

BusinessUpdate Highlights

---

“I am happy to report that PAVmed and its subsidiaries are making solid progress on all fronts and are laying a solid foundation for us to continue driving our long-term growth strategy and mission to create a leading, diversified medical technology company,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “This includes EsoGuard commercialization, advancing our Veris Health portfolio, CarpX’s limited commercial release, preparing to commercially launch NextFlo, PortIO first-in-human cases, and advancing the rest of our portfolio towards commercialization. Over the past several quarters we have transformed our business model, expanded our infrastructure and substantially grown our team to accommodate our transition from a technology-focused to a commercial-focused enterprise.”

●	Lucid<br> processed 303 commercial EsoGuard tests in the fourth quarter of 2021, which represents an approximately 50% increase sequentially<br> from the third quarter and a nearly 200% increase annually from the fourth quarter of 2020. The Lucid Test Center program completed<br> its first stage and now covers seven metropolitan areas in the Southwest and Pacific Northwest. Lucid is now launching the next stage<br> of the program, with accelerated expansion into nine larger states. Lucid significantly expanded its sales infrastructure and operations.<br> The team now consists of twenty-two sales professionals including ten sales representatives. It expects team to double in size and<br> the number of sales reps to triple by the end of the calendar year.
●	LucidDx<br> Labs, a wholly owned subsidiary of Lucid, acquired the assets to operate its own new CLIA-certified, CAP-accredited clinical laboratory<br> where it is now performing all EsoGuard testing. LucidDx Labs has upgraded its revenue cycle management provider and will start submitting<br> Medicare claims using the effective $1938 Medicare payment rate. It continues to wait for Medicare Administrative Contractor Palmetto<br> GBA’s MolDx program to issue a draft local coverage determination (LCD). The laboratory has been submitting claims to private<br> payors and has been receiving approximately $1,150 per test representing approximately 60% out-of-network coverage.
---	---
●	Veris<br> is successfully advancing its software, device, and data programs with the help of world-class technology and medical advisory boards<br> and working very closely with Microsoft, as a member of its Global Partner program, and its software development partner, Loka Inc.<br> The software platform is on schedule to launch commercially in 2H2022. Veris is hiring a Chief Commercial Officer and building its<br> own data & analytics team to advance its data monetization strategy.
●	Veris<br> successfully completed feasibility animal testing of multiple prototypes of an implantable device as well as an FDA pre-submission<br> meeting. Based on FDA feedback it has developed a three-phase pipeline strategy, an initial platform launch in 2H2022 with wearables<br> and connected medical devices, a subsequent FDA 510(k) path clearance of separate implantable monitoring device to be implanted alongside<br> a traditional port, and an FDA de novo and EU CE Mark path for a fully integrated intelligent vascular access port.
●	NextFlo<br> product development is progressing well with FDA submission and commercial launch targeted for the second half of this year. PAVmed<br> has hired a VP, Sales for NextFlo who is working closely with Deloitte to lay the foundation for commercial launch targeting inpatient,<br> outpatient, and home infusions.
●	CarpX<br> continues with its limited commercial release utilizing early adopter key opinion leaders to advance procedural and product improvements.<br> Eight new surgeons have been trained and five more are scheduled for training. Seven CarpX cases were performed in the fourth quarter<br> of 2021. Clinical cases were then held to implement the product improvements and will restart this coming quarter. Development of<br> next generation CarpX device incorporating integrated ultrasound imaging is progressing well.
●	PortIO<br> launched its first-in-human clinical study in Colombia, South America with three successful implants. Although the Company remains<br> engaged with FDA regarding its requirements for an IDE study, it has expanded its strategy to pursue a European study to support<br> EU CE Mark clearance and provide additional human data for U.S. approval.
●	In<br> March 2022, both the PAVmed and Lucid board of directors approved entering into an intercompany license between PAVmed and Lucid<br> such that Lucid will be granted the rights to commercialize EsoCure for the endoscopic treatment of late esophageal precancer (dysplastic<br> Barrett’s Esophagus), including a royalty arrangement whereby Lucid will pay PAVmed a 5% royalty on all EsoCure sales up to<br> $100 million per calendar year, and 8% above that threshold.
---	---
●	In<br> March 2022, both the PAVmed and Lucid board of directors approved entering into a purchase and sale of the CapNostics, LLC assets,<br> including the EsophaCap^®^ non-endoscopic sponge-based esophageal cell collection device, from PAVmed to Lucid as well<br> as transferring the consulting agreement with the principal owner of CapNostics, LLC prior to the purchase by PAVmed on October 5,<br> 2021.

PreliminaryFinancial Results

●	For<br> the fourth quarter of 2021, EsoGuard related revenues were $0.3 million while for the year ended December 31, 2021, revenues were<br> $0.5 million. Fourth-quarter and full-year 2021 operating expenses were approximately $19.5 million and $54.3 million, respectively,<br> which include stock-based compensation expenses of $4.4 million and $15.0 million, respectively. GAAP net loss attributable to shareholders<br> for the fourth quarter and full-year 2021 were approximately $17.3 million and $50.6 million, or $(0.20) and $(0.65) per common share.
●	As<br> shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on<br> the Company’s financial results, the Company’s preliminary non-GAAP adjusted loss for the fourth quarter and year ended<br> December 31, 2021, were approximately $12.7 million and $33.2 million or $(0.15) and $(0.43) per common share.
●	PAVmed<br> had cash and cash equivalents of $77.3 million as of December 31, 2021, compared with $17.3 million as of December 31, 2020.
●	On<br> March 28, 2022, PAVmed’s majority-owned subsidiary, Lucid Diagnostics, Inc. entered into a Common Stock Purchase Agreement<br> (the “Purchase Agreement”) with CF Principal Investments LLC (“Cantor”), an affiliate of Cantor Fitzgerald,<br> relating to a committed equity facility (the “Facility”). Pursuant to the Purchase Agreement, Lucid has the right to<br> sell to Cantor up to $50.0 million of its common shares (the “Shares”), subject to certain conditions and limitations<br> set forth in the Purchase Agreement. While there are distinct differences, the Facility is structured similarly to a traditional<br> at-the-market equity facility, insofar as it allows Lucid to raise primary equity capital on a periodic basis at a price related<br> to the current market price.
●	Sales<br> of the Shares to Cantor under the Purchase Agreement, and the timing of any sales, will be determined by the Company from time to<br> time at its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the trading<br> price of the Shares and determinations by the Company regarding the use of proceeds of such Shares. Upon the satisfaction of the<br> conditions to Cantor’s obligation to purchase Shares, Lucid will have the right, from time to time during the 36-month period<br> after the commencement of the Facility, to direct Cantor to purchase up to a maximum number of Shares on any trading day. The purchase<br> price of the Shares will be 96% of the volume-weighted average price of the Shares on such trading day.

The unaudited financial results for the year ended December 31, 2021, will be filed with the SEC on Form 10-K in the coming days and will be available at www.pavmed.com or www.sec.gov.

PAVmedNon-GAAP Measures

To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.

Non-GAAP financial measures are presented with the intent of providing greater transparency to information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from or as an alternative to, the most directly comparable GAAP financial measures.

Non-GAAP financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.

A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the fourth quarter and year ended December 31, 2021, and 2020 is as follows:

	For the three months ended December 31,						For the year ended<br><br> <br>December 31,
	2021			2020			2021			2020
Revenue	$	300		$	-		$	500		$	-
Gross profit		(229	)		-			(85	)		-
Operating expenses		19,538			7,556			54,308			23,351
Loss from operations		(19,767	)		(7,556	)		(54,393	)		(23,351	)
Net income (loss) per common share, basic and diluted	$	(0.20	)	$	(0.14	)	$	(0.65	)	$	(0.73	)
Net loss attributable to common stockholders		(17,285	)		(8,812	)		(50,630	)		(34,563	)
Preferred Stock dividends and deemed dividends		67			72			283			287
Net income (loss) as reported		(17,218	)		(8,740	)		(50,347	)		(34,276	)
Adjustments:
Depreciation  and amortization expense^1^		166			6			226			23
Interest expense, net^2^		-			-			-			53
EBITDA		(17,052	)		(8,734	)		(50,121	)		(34,200	)
Other non-cash or financing related expenses:
Stock-based compensation expense^3^		4,380			586			15,009			2,044
Debt extinguishment/debt forgiveness^2^		-			1,897			3,415			6,497
Acquisition related^1^		-			-			133			-
Change in FV convertible debt^2^		-			(194	)		(1,682	)		5,327
Offering costs convertible debt^2^		-			-			-			660
Non-GAAP adjusted (loss)		(12,672	)		(6,445	)		(33,246	)		(19,672	)
Basic and Diluted shares outstanding		86,368			63,820			77,516			47,432
Non-GAAP adjusted (loss) income per share	$	(0.15	)	$	(0.10	)	$	(0.43	)	$	(0.41	)

^1^ Included in general and administrative expenses in the financial statements

^2^ Included in other income and expenses

^3^ Stock-based compensation ("SBC") expenses:

(ooo's except per-share amounts)	For the three months ended December 31,						For the year ended   December 31,
	2021			2020			2021			2020
Commercial operations expense total		3,103			1,257			8,895			2,789
Stock-based compensation expense		(337	)		(95	)		(1,177	)		(278	)
Net commercial operations expense excluding SBC		2,766			1,162			7,718			2,511
General and administrative expense total		9,466			2,657			25,566			9,599
Stock-based compensation expense		(3,737	)		(356	)		(12,799	)		(1,304	)
Net general and administrative expense excluding SBC 5,729					2,301			12,767			8,295
Research and development expense total		6,969			3,642			19,847			10,963
Stock-based compensation expense		(306	)		(135	)		(1,033	)		(462	)
Net research and development expense excluding SBC 6,663					3,507			18,814			10,501
Total operating expenses		19,538			7,556			54,308			23,351
Stock-based compensation expense		(4,380	)		(586	)		(15,009	)		(2,044	)
Net operating expenses excluding SBC		15,158			6,970			39,299			21,307

LucidDiagnostics (Nasdaq: LUCD) Preliminary Financial Results

●	For<br> the fourth quarter of 2021, EsoGuard related revenues were $0.3 million, while for the year ended December 31, 2021, revenues were<br> $0.5 million. Fourth-quarter and full-year 2021 operating expenses were approximately $11.1 million and $27.3 million, respectively,<br> which include stock-based compensation expenses of $3.2 million and $9.6 million, respectively. GAAP net loss attributable to common<br> stockholders for the fourth quarter and full-year 2021 were approximately $11.3 million and $28.1 million, or $(0.32) and $(1.51)<br> per common share.
●	As<br> shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on<br> the Company’s financial results, the Company’s preliminary non-GAAP adjusted loss for the fourth quarter and year ended<br> December 31, 2021, were approximately $7.7 million and $17.8 million or $(0.22) and $(0.96) per common share.
●	Lucid<br> had cash and cash equivalents of $53.7 million as of December 31, 2021, compared to $0.1 million as of December 31, 2020.
●	On<br> March 28, 2022, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with CF Principal<br> Investments LLC (“Cantor”), an affiliate of Cantor Fitzgerald, relating to a committed equity facility (the “Facility”).<br> Pursuant to the Purchase Agreement, the Company has the right to sell to Cantor up to $50.0 million of its common shares (the “Shares”),<br> subject to certain conditions and limitations set forth in the Purchase Agreement. While there are distinct differences, the Facility<br> is structured similarly to a traditional at-the-market equity facility, insofar as it allows the Company to raise primary equity<br> capital on a periodic basis at a price related to the current market price.
●	Sales<br> of the Shares to Cantor under the Purchase Agreement, and the timing of any sales, will be determined by the Company from time to<br> time at its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the trading<br> price of the Shares and determinations by the Company regarding the use of proceeds of such Shares. Upon the satisfaction of the<br> conditions to Cantor’s obligation to purchase Shares, the Company will have the right, from time to time during the 36-month<br> period after the commencement of the Facility, to direct Cantor to purchase up to a maximum number of Shares on any trading day.<br> The purchase price of the Shares will be 96% of the volume-weighted average price of the Shares on such trading day.
●	The<br> unaudited financial results for the year ended December 31, 2021, will be filed with the SEC on Form 10-K in the coming days and<br> will be available at www.luciddx.com or www.sec.gov.

LucidNon-GAAP Measures

---

●	To<br> supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management<br> provides certain non-GAAP financial measures of the Company’s financial results. These non-GAAP financial measures include<br> net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA<br> for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of<br> EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.
●	Non-GAAP<br> financial measures are presented with the intent of providing greater transparency to the information used by us in our financial<br> performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information<br> to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical<br> financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not<br> intended to be, and should not be, a substitute for, considered superior to, considered separately from or as an alternative to,<br> the most directly comparable GAAP financial measures.
●	Non-GAAP<br> financial measures are provided to enhance readers’ overall understanding of our current financial results and to provide further<br> information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management<br> and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business<br> outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the<br> reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value<br> of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance.<br> In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.

A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the fourth quarter and year ended December 31, 2021, and 2020 is as follows:

---

---

	For the three months ended December 31,						For the year ended  December 31,
	2021			2020			2021			2020
Revenue	$	300		$	-		$	500		$	-
Gross profit		(141	)		-			(85	)		-
Operating expenses		11,100			2,731			27,334			8,280
Interest expense		65			-			659			-
Net loss		(11,306	)		(2,731	)		(28,078	)		(8,280	)
Net income (loss) per common share, basic and diluted	$	(0.32	)	$	(0.19	)	$	(1.51	)	$	(0.59	)
Adjustments:
Depreciation  and amortization expense^1^		-			-			3			-
Interest expense, net^3^		65			-			659			-
EBITDA		(11,241	)		(2,731	)		(27,416	)		(8,280	)
Other non-cash or financing related expenses:
Stock-based compensation expense^3^		3,542			16			9,599			65
Non-GAAP adjusted (loss)		(7,699	)		(2,715	)		(17,817	)		(8,215	)
Basic and Diluted shares outstanding		34,918			14,115			18,604			14,114
Non-GAAP adjusted (loss) income per share	$	(0.22	)	$	(0.19	)	$	(0.96	)	$	(0.58	)

^1^ Included in general and administrative expenses in the financial statements

^2^ Included in other income and expenses

	For the three months ended December 31,						For the year ended December 31,
	2021			2020			2021			2020
3 Stock-based compensation ("SBC") expenses:
Commercial operations expense total		2,571			633			5,260			1,305
Stock-based compensation expense		-			-			(210	)		-
Net commercial operations expense excluding SBC		2,571			633			5,050			1,305
General and administrative expense total		5,047			272			12,778			1,532
Stock-based compensation expense		(3,123	)		-			(9,111	)		-
Net general and administrative expense excluding SBC		1,924			272			3,667			1,532
Research and development expense total		3,482			1,826			9,296			5,443
Stock-based compensation expense		(110	)		(16	)		(278	)		(65	)
Net research and development expense excluding SBC		3,372			1,810			9,018			5,378
Total operating expenses		11,100			2,731			27,334			8,280
Stock-based compensation expense		(3,233	)		(16	)		(9,599	)		(65	)
Net operating expenses excluding SBC		7,867			2,715			17,735			8,215

---

---

AboutPAVmed

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), markets the EsoGuard^®^ Esophageal DNA Test and EsoCheck^®^Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX^®^ Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure™ Esophageal Ablation Device with Caldus™ Technology, which complements EsoGuard and EsoCheck, the NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable Intraosseous Vascular Access Device, novel pediatric ear tubes, mechanical circulatory support technology and glucose monitoring. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

AboutLucid Diagnostics

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building nationwide direct sales and marketing team targeting primary care physicians, gastroenterologists, and consumers, as well as a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing. For more information, please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

---

Forward-LookingStatements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s and Lucid’s common stock; PAVmed’s Series W and Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s and Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s and Lucid’s clinical and preclinical studies; whether and when PAVmed’s and Lucid’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and Lucid’s products once cleared and commercialized; PAVmed’s and Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, PAVmed and Lucid have been monitoring the COVID-19 pandemic and the pandemic’s impact on PAVmed’s and Lucid’s businesses. PAVmed and Lucid expect the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, to be dictated by, among other things, the success f efforts to contain the pandemic and the impact of such efforts on PAVmed’s and Lucid’s businesses. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s and Lucid’s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s and Lucid’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report and Lucid’s Registration Statement No. 333-259721 filed with the Securities and Exchange Commission. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Contacts

Investors

Adrian K. Miller

PAVmed Inc.

AKM@PAVmed.com

Media

Shani Lewis

LaVoieHealthScience

(609) 516-5761

PAVmed@lavoiehealthscience.com